172649-40-0

Basic information

• Product Name: 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE
• Synonyms: 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE;ZD0947
• CAS NO: 172649-40-0
• Molecular Formula: C17H13F3N2O
• Molecular Weight: 318.29
• Mol File: 172649-40-0.mol

Chemical Properties

• Boiling Point: 420.402°C at 760 mmHg
• Flash Point: 208.052°C
• Appearance: /
• Density: 1.365g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE(172649-40-0)
• EPA Substance Registry System: 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE(172649-40-0)

Safety Data

• Hazardous Substances Data: 172649-40-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals due to its unique structure and properties. The presence of the hexahydroquinoline moiety and the trifluoromethyl group makes it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE is utilized as a key intermediate in the synthesis of bioactive compounds. Its structural features allow for the creation of new molecules with potential therapeutic effects, making it an important tool in drug discovery and optimization processes.
Used in Drug Design:
3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE is employed as a structural element in drug design, where its unique properties can be leveraged to create novel molecules with improved pharmacological profiles. The hexahydroquinoline ring and trifluoromethyl group can be used to modulate the activity, selectivity, and pharmacokinetics of drug candidates, leading to the development of more effective and safer therapeutic agents.
Used in Agrochemical Development:
In the agrochemical industry, 3-[(4S)-5-OXO-2-(TRIFLUOROMETHYL)-1,4,5,6,7,8-HEXAHYDROQUINOLIN-4-YL]BENZONITRILE is used as a starting material for the synthesis of new agrochemicals with potential applications in pest control, crop protection, and other agricultural settings. Its unique structural features can be harnessed to develop compounds with improved efficacy, selectivity, and environmental compatibility.

InChI:InChI=1/C17H13F3N2O/c18-17(19,20)15-8-12(11-4-1-3-10(7-11)9-21)16-13(22-15)5-2-6-14(16)23/h1,3-4,7-8,12,22H,2,5-6H2/t12-/m0/s1

Upstream product

• 852613-29-7 4-(3-cyano-phenyl)-5-oxo-2-trifluoromethyl-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid 3-methyl-but-2-enyl ester 
• 852613-19-5 4-(3-cyano-phenyl)-2-hydroxy-5-oxo-2-trifluoromethyl-1,2,3,4,5,6,7,8-octahydro-quinoline-3-carboxylic acid 3-methyl-but-2-enyl ester 
• 852807-93-3 4-(3-Cyano-phenyl)-2-hydroxy-5-oxo-2-trifluoromethyl-1,2,3,4,5,6,7,8-octahydro-quinoline-3-carboxylic acid (E)-3,7-dimethyl-octa-2,6-dienyl ester 
• 852613-30-0 4-(3-Cyano-phenyl)-5-oxo-2-trifluoromethyl-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid (E)-3,7-dimethyl-octa-2,6-dienyl ester 
• 24964-64-5 3-Cyanobenzaldehyde 
• 172649-33-1 (-)-4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid 
• 504-02-9 1,3-cylohexanedione 
• 101048-56-0 3-(4,4,4-Trifluoro-3-oxo-1-butenyl)benzonitrile 
• 395060-15-8 (R)-3-[(1-Phenylethyl)amino]-2-cyclohexen-1-one 

Relevant articles and documents

Alternative esters in the synthesis of ZD0947

Alternatives to the original iso-borneol and allyl esters were investigated in the synthesis of ZD0947 (1). Homologous allylic esters were prepared in higher yields and were more readily purified than for the existing route, but offered no further benefits later in the synthesis. However, the PNB-substituted ester series provided crystalline intermediates, higher yields and simplified isolations through-out, and utilised a heterogeneous hydrogenation, thus reducing the residual catalyst levels.

Process for asymmetric synthesis of substituted 1,4 -dihydropyridines

A process is described for reacting a vinylogous amide with an α,β-unsaturated ketone in the presence of a silicon compound to form an 1,5-diketone which is converted to a 1,4-dihydropyridine. Asymmetric substituted 1,4-dihydropyridines are synthesized by

An asymmetric synthesis of a 4-substituted-1,4-dihydropyridine

A concise, convergent asymmetric synthesis of the 4-substituted-1,4-dihydropyridine 1 [Ohnmacht, C. J., Jr.; Trainor, D. A.; Forst, J. M.; Stein, M. M.; Harris, R. J. Patent No. 5,622, 964] has been achieved via a novel asymmetric Michael addition of an o

QUINOLONE DERIVATIVE FOR TREATMENT OF URINARY INCONTINENCE

(S)-(-)-4-(3-cyanophenyl)-2-trifluoromethyl-4,6,7,8-tetrahydro-5(1H)quinolone as a potassium channel opener, useful for treating urinary incontinence, and processes for the preparation thereof.

Heterocyclic derivatives

Compounds of formula I STR1 wherein R2, R3, R4, R10 and R11 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinery incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.